Loading
LILRB2 is a brake on monocytes and dendritic cells that reads HLA-G and other HLA class I molecules and keeps them in a tolerant, tumour-friendly state. The antibody MK-4830 blocks it and is in phase 2 with pembrolizumab.
LILRB2 (chromosome 19q13.42) is a receptor for class I MHC antigens across HLA-A, B, C, G and F that is involved in down-regulating the immune response and developing tolerance, and recognises peptide-bound HLA-G with beta-2 microglobulin; it is expressed in monocytes, at lower levels in myeloid and plasmacytoid dendritic cells, in tolerogenic IL-10-producing dendritic cells, in myeloid-derived suppressor cells during pregnancy, at low levels in NK cells and in B cells (UniProt Q8N423). MK-4830 is in phase 2 studies with pembrolizumab, including a completed study with chemotherapy in ovarian cancer (NCT05446870) and a platform study in solid tumours (NCT04895722).
In plain words · LILRB2 is a brake on monocytes and dendritic cells that reads HLA-G and other HLA class I molecules and keeps them in a tolerant, tumour-friendly state. The antibody MK-4830 blocks it and is in phase 2 with pembrolizumab.
LILRB2 is a brake on monocytes and dendritic cells that reads HLA-G and other HLA class I molecules and keeps them in a tolerant, tumour-friendly state. The antibody MK-4830 blocks it and is in phase 2 with pembrolizumab.
An ITIM-bearing LILR of myeloid cells; the murine orthologue PIRB regulates myeloid-derived suppressor cell development and a tumour-permissive microenvironment (van der Touw et al. 2017).
No product in this corpus aims at LILRB2 (ILT4) yet. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
First described 1997. Earliest sequence paper UniProt cites for the protein: Wagtmann et al, Curr. Biol, 1997, "A new human gene complex encoding the killer cell inhibitory receptors and related monocyte/macrophage receptors". Source.
Sources: HGNC HGNC:6606 (approved symbol, name, aliases and cross-references); UniProt Q8N423 (protein name, function and tissue specificity)
An ITIM-bearing LILR of myeloid cells; the murine orthologue PIRB regulates myeloid-derived suppressor cell development and a tumour-permissive microenvironment (van der Touw et al. 2017).
Query for this target: (TITLE:"LILRB2" OR ABSTRACT:"LILRB2" OR TITLE:"ILT4" OR ABSTRACT:"ILT4" OR TITLE:"LIR-2" OR ABSTRACT:"LIR-2" OR TITLE:"CD85d" OR ABSTRACT:"CD85d" OR TITLE:"leukocyte immunoglobulin like receptor B2" OR ABSTRACT:"leukocyte immunoglobulin like receptor B2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LILRB2 (ILT4), not a curated reading list.
Shares HLA-A, Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle, Pembrolizumab and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle, Ovarian cancer and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.